This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: November 27, 2007
Last updated: February 25, 2015
Last verified: February 2015
This study will investigate the influence of MK0859 on ambulatory blood pressure, and how safe and tolerable MK0859 is on the subjects This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition Intervention Phase
Ambulatory Blood Pressure Drug: MK0859 Phase 1

Study Type: Interventional

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 22
Study Start Date: July 2006
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • You are between the ages of 45-75
  • You are a man or non-pregnant woman
  • You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication

Exclusion Criteria:

  • You have smoked or used other nicotine-containing products (chewing tobacco) within the last 6 months
  • You have used St. John's Wort or any products that include it within the last 2 weeks
  • You have used herbal, organic, dietary or nutritional remedies within the last 2 weeks
  • You have a history of drug allergies (anaphylaxis, angioedema)
  • You have taken an investigational drug in another clinical trial within the last 4 weeks
  • You have a history of cardiovascular disease including hypertension (high blood pressure)
  • You have a history of renal disease
  • You have a history of gall bladder disease or have had abnormal liver function tests
  • You have a history of drug or alcohol abuse
  • You drink more than 6 cups of caffeinated beverages a day (coffee, tea or cola)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00565006

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00565006     History of Changes
Other Study ID Numbers: 0859-012
Study First Received: November 27, 2007
Last Updated: February 25, 2015

Additional relevant MeSH terms:
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on September 21, 2017